Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-04-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于使用自有资金支付募投项目部分款项并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the use of self-owned funds to pay for part of the fundraising investment projects and subsequent replacement with raised funds. It details the board and supervisory approvals, independent director opinions, and sponsor institution verification. The content focuses on the company's capital management and fundraising project fund usage, specifically about replacing self-owned funds with raised funds. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. The document is relatively short (3999 characters) and is an announcement about capital usage and replacement procedures related to fundraising. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2022-04-28 Chinese
圣湘生物科技股份有限公司关于使用部分超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 圣湘生物科技股份有限公司 regarding the use of part of the over-raised funds to permanently supplement working capital. It details the board and supervisory committee approvals, independent director opinions, and the need for shareholder meeting approval. The document references regulatory compliance and fundraising details but does not contain financial statements or detailed financial performance data. It is a formal announcement about capital usage and financing activities rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2508 characters, which is consistent with an announcement rather than a full report.
2022-04-28 Chinese
圣湘生物科技股份有限公司第一届监事会2022年第三次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of the company. It details the meeting date, attendance, and specific resolutions approved, including the use of funds, profit distribution, and capital increase proposals. It does not contain financial statements or detailed financial data but rather reports on governance decisions and approvals that will be submitted to the shareholders' meeting. The document length is short (1775 characters), and it is an announcement of meeting resolutions rather than a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific report types.
2022-04-28 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司使用部分超募资金永久补充流动资金之专项核查意见
Regulatory Filings
2022-04-28 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase through centralized bidding on the Shanghai Stock Exchange. It details the number of shares repurchased, prices, total funds used, and references the company's board approval and regulatory compliance. The document is short (1107 characters) and focuses on the share buyback activity rather than financial results or reports. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares.
2022-04-21 Chinese
圣湘生物科技股份有限公司2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021. The content includes detailed descriptions of internal control scope, standards, defect recognition, and remediation status. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document length is 3934 characters, which is relatively short but contains substantive content on internal control evaluation, not just an announcement or certification. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, including internal control evaluations. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.